Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 255-265

  Etulain, J ^a   Fondevila, C ^b   Negrotto, S ^a   Schattner, M ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Interventional Cardiology Department   (Argentina)

Author keywords

alpha granules; angiogenesis; aspirin; platelet; VEGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYLSALICYLIC ACID; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CCL1 CHEMOKINE; ENDOSTATIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; PLATELET DERIVED GROWTH FACTOR BB; RANTES; SOMATOMEDIN C; THROMBIN; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; THROMBOCYTE ACTIVATION;

ALPHA-GRANULES; ANGIOGENESIS; ASPIRIN; PLATELET; VEGF;

ASPIRIN; BLOOD PLATELETS; CELL PROLIFERATION; ENDOSTATINS; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881263897     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12250     Document Type: Article

References (42)

1. Albini A, Tosetti F, Li VW, Noonan DM, Li WW, (2012). Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9: 498-509.
2. Alexander S, Harmar A, McGrath I, (2011). New updated GRAC Fifth Edition with searchable online version Launch of new portal Guide to Pharmacology in association with NC-IUPHAR Transporter-Themed Issue. Br J Pharmacol 164: 1749-1750.
3. Arnaoutova I, George J, Kleinman HK, Benton G, (2009). The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 12: 267-274.
4. Bambace NM, Holmes CE, (2011). The platelet contribution to cancer progression. J Thromb Haemost 9: 237-249.
5. Bambace NM, Levis JE, Holmes CE, (2010). The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 21: 85-93.
6. Battinelli EM, Markens BA, Italiano JE, Jr, (2011). Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118: 1359-1369.
7. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM, (2006). Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20: 2009-2016.
8. Carmeliet P, (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-936.
9. Chatterjee M, Huang Z, Zhang W, Jiang L, Hultenby K, Zhu L, et al. (2011). Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 117: 3907-3911.
10. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. (2012). Platelets increase the proliferation of ovarian cancer cells. Blood 120: 4869-4872.
11. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, et al. (2007). Moderation of the platelet releasate response by aspirin. Blood 109: 4786-4792.
12. Etulain J, Lapponi MJ, Patrucchi SJ, Romaniuk MA, Benzadon R, Klement GL, et al. (2011). Hyperthermia inhibits platelet hemostatic functions and selectively regulates the release of alpha-granule proteins. J Thromb Haemost 9: 1562-1571.
13. Etulain J, Negrotto S, Carestia A, Pozner RG, Romaniuk MA, D'Atri LP, et al. (2012). Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 107: 99-110.
14. Han N, Jin K, He K, Cao J, Teng L, (2011). Protease-activated receptors in cancer: a systematic review. Oncol Lett 2: 599-608.
15. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD, (2008). Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 68: 6851-6858.
16. Italiano JE, Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. (2008). Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111: 1227-1233.
17. Jonnalagadda D, Izu LT, Whiteheart SW, (2012). Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 120: 5209-5216.
18. Kamykowski J, Carlton P, Sehgal S, Storrie B, (2011). Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet alpha-granules. Blood 118: 1370-1373.
19. Kim KW, Moretti L, Lu B, (2008). M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS ONE 3: e2275.
20. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, et al. (2009). Platelets actively sequester angiogenesis regulators. Blood 113: 2835-2842.
21. Li Z, Delaney MK, O'Brien KA, Du X, (2010). Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30: 2341-2349.
22. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, et al. (2005). Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 102: 216-220.
23. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF, (1998). In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275 (3 Pt 2): H1054-H1061.
24. Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L, (2008). Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 99: 305-315.
25. Mohle R, Green D, Moore MA, Nachman RL, Rafii S, (1997). Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94: 663-668.
26. Moser M, (2008). The role of thrombin in angiogenesis. Hamostaseologie 28: 189-194.
27. Negrotto S, Malaver E, Alvarez ME, Pacienza N, D'Atri LP, Pozner RG, et al. (2006). Aspirin and salicylate suppress polymorphonuclear apoptosis delay mediated by proinflammatory stimuli. J Pharmacol Exp Ther 319: 972-979.
28. van Nispen tot Pannerden H, de Haas F, Geerts W, Posthuma G, van Dijk S, Heijnen HF, (2010). The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes. Blood 116: 1147-1156.
29. Patzelt J, Langer HF, (2012). Platelets in Angiogenesis. Curr Vasc Pharmacol 10: 570-577.
30. Peterson JE, Zurakowski D, Italiano JE, Jr, Michel LV, Fox L, Klement GL, et al. (2010). Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 85: 487-493.
31. Peterson JE, Zurakowski D, Italiano JE, Jr, Michel LV, Connors S, Oenick M, et al. (2012). VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 15: 265-273.
32. Pietramaggiori G, Scherer SS, Cervi D, Klement G, Orgill DP, (2008). Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit. Am J Pathol 173: 1609-1616.
33. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME, (1998). Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 125: 1252-1257.
34. Radziwon-Balicka A, Moncada de la Rosa C, Jurasz P, (2012). Platelet-associated angiogenesis regulating factors: a pharmacological perspective. Can J Physiol Pharmacol 90: 679-688.
35. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z, (2012). Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379: 1591-1601.
36. Sabrkhany S, Griffioen AW, Oude Egbrink MG, (2011). The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 1815: 189-196.
37. Sehgal S, Storrie B, (2007). Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 5: 2009-2016.
38. Sennino B, McDonald DM, (2012). Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12: 699-709.
39. Thun MJ, Jacobs EJ, Patrono C, (2012). The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9: 259-267.
40. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, et al. (2005). Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314: 522-532.
41. Weis SM, Cheresh DA, (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: 1359-1370.
42. Yu P, Yu DM, Qi JC, Wang J, Zhang QM, Zhang JY, et al. (2006). [High d-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction]. Zhonghua Yi Xue Za Zhi 86: 3425-3430.